In recent years, anti-CD19 chimeric antigen receptor (CAR) T-cell therapies have been widely used for hematologic tumors, among which anti-CD19 CAR T-cell therapies can achieve complete remission (CR) rates of 70–90% for B-ALL [7,8,9]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.